Retreatment with purine analogs in patients with chronic lymphocytic leukemia.

Abstract excerpt

We evaluated the efficacy and toxicity of retreatment with purine analogs (PA) in 62 patients with relapsed chronic lymphocytic leukemia. Median OS and PFS after retreatment were 60 and 26 months, respectively. By multivariate analysis, minimal residual disease status, ZAP-70 expression and age had independent predictive power in terms of OS. Toxicity was mainly neutropenia (21%) and infections (39%). Second...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacterial Infections
• Share to Leukemia, Lymphocytic, Chronic, B-Cell